Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial

Authors:

Abstract
No abstract available
Funding Information
  • Regeneron Pharmaceuticals Inc
  • Sanofi US

This publication has 17 references indexed in Scilit: